Combatting chemoresistance in GBM

Combatting chemoresistance in GBM
By using a combinational therapeutic strategy, a research team have created a promising approach to combat chemoresistance in GBM. Glioblastoma often resists front-line chemotherapies, including temozolomide, a drug that damages DNA and triggers tumour cell death. Nearly half of glioblastoma patients resist the treatment by producing a DNA-repairing enzyme, MGMT, but until recently it wasn’t clear why temozolomide wasn’t working for patients who lacked the MGMT enzyme. Using glioblast...

Comments

Popular posts from this blog

The world's longest indoor test track for self-driving vehicles

Spar Uttoxeter sold to experienced forecourt operator through Christie & Co

Advanced AI solution to meet retailers’ critical need for smarter merchandising